Company intelligence / Profile preview
Oricula Therapeutics
Seattle, Washington, United Statesoricularx.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Oricula’s lead compound, ORC-13661, has received FDA clearance for an Investigational New Drug (IND) application and has entered early human clinical trials. The company aims to develop the first approved medication that prevents aminoglycoside antibiotic-induced hearing loss. Preclinical data show high potency and favorable drug-like properties.
- Therapeutic areas
- Neurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
University of WashingtonNIDCDNIAIDState of Washington Life Sciences Discovery FundNIH BPN/NINDS Blueprint Neurotherapeutics Program
Beyond the preview
Go deeper on Oricula Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oricula Therapeutics.